These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer. Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897 [TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316 [TBL] [Abstract][Full Text] [Related]
27. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583 [TBL] [Abstract][Full Text] [Related]
28. Response and Prognosis of Docetaxel and Cyclophosphamide as Neoadjuvant Chemotherapy in ER Hayashi N; Yagata H; Tsugawa K; Kajiura Y; Yoshida A; Takei J; Yamauchi H; Nakamura S Clin Breast Cancer; 2020 Dec; 20(6):462-468. PubMed ID: 33046356 [TBL] [Abstract][Full Text] [Related]
29. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy? Coelho RC; Da Silva FML; Do Carmo IML; Bonaccorsi BV; Hahn SM; Faroni LD Breast; 2017 Feb; 31():192-196. PubMed ID: 27889595 [TBL] [Abstract][Full Text] [Related]
30. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071 [TBL] [Abstract][Full Text] [Related]
31. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708 [TBL] [Abstract][Full Text] [Related]
32. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer. Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368 [TBL] [Abstract][Full Text] [Related]
33. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients. Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C Breast J; 2014; 20(4):381-7. PubMed ID: 24890310 [TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy]. Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696 [TBL] [Abstract][Full Text] [Related]
35. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease. Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596 [TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB. Kim R; Osaki A; Tanabe K; Toge T Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565 [TBL] [Abstract][Full Text] [Related]
37. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy. Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695 [TBL] [Abstract][Full Text] [Related]
38. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study. Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642 [TBL] [Abstract][Full Text] [Related]
39. Effect of Neoadjuvant Chemotherapy on the Surgical Treatment of Patients With Locally Advanced Breast Cancer Requiring Initial Mastectomy. Barranger E; Antomarchi J; Chamorey E; Cavrot C; Flipo B; Follana P; Peyrottes I; Chapellier C; Ferrero JM; Ihrai T Clin Breast Cancer; 2015 Oct; 15(5):e231-5. PubMed ID: 25887149 [TBL] [Abstract][Full Text] [Related]
40. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Shin HC; Han W; Moon HG; Im SA; Moon WK; Park IA; Park SJ; Noh DY Ann Surg Oncol; 2013 Aug; 20(8):2582-9. PubMed ID: 23504119 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]